125P A phase IIa study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab ("PAVE") in advanced non-small cell lung cancer (NSCLC) patients (pts). (December 2022) - Imbimbo, M.; Ghisoni, E.; Mulvey, A.; Bouchaab, H.; Mederos Alfonso, N.; Karp, D.; Camidge, D.R.; Mansfield, A.S.; Yim, C.Y.; Ames, T.D.; Price, M.; Baeck, J.; et al.